PMOS
Insulin-resistance & hyperandrogenism driven; ovulation is downstream, so metabolic correction leads.
Decision support, not prescription. You decide.
Warning — Topical peptide/growth-factor serums worsen hirsutism
Speed hair growth and cannot distinguish skin from hair — avoid topical peptide serums on the face in PCOS/hirsutism.
Candidate agents
4 agents · tap to expand▶SemaglutideLeadStrongA GLP-1 receptor agonist used off-label in PCOS as a metabolic lever: it drives real weight loss and lowers testosterone, but its reproductive payoff (cycles, ovulation) is inferred downstream, not directly proven. Take the metabolic effect seriously; treat the fertility claim as provisional.expand
A GLP-1 receptor agonist used off-label in PCOS as a metabolic lever: it drives real weight loss and lowers testosterone, but its reproductive payoff (cycles, ovulation) is inferred downstream, not directly proven. Take the metabolic effect seriously; treat the fertility claim as provisional.
▸Full clinical story
PCOS here is framed as insulin-resistance- and hyperandrogenism-driven, with anovulation downstream. Semaglutide reduces adiposity and improves insulin sensitivity, which lowers ovarian and adrenal androgen output and raises SHBG; the hypothesis is that correcting the metabolic driver relieves the hyperandrogenic brake on the HPO axis and allows cycles to normalize.
Honest grade: emerging. Weight loss from GLP-1 RAs is established at RCT/guideline level in obesity, and the 2023 International PCOS Guideline conditionally supports them for anthropometric outcomes. But PCOS-specific data are mostly small trials of liraglutide, with semaglutide represented by small mechanistic RCTs (e.g. a 20-woman placebo-controlled study of gastric emptying in PCOS + obesity); weight and testosterone reductions are consistent while effects on ovulation/fertility are not directly demonstrated. Downgraded from 'strong' to 'emerging' because the therapeutic package for PCOS (androgens + reproductive endpoints) rests on small/short human trials, not PCOS ovulation RCTs.
Anecdotal community signal only: PCOS patients widely report starting semaglutide (or tirzepatide) for weight and describe returning menses, easier weight loss, and reduced cravings within months; many titrate slowly to limit nausea and some 'microdose' below diabetes/obesity label doses to manage tolerability. A recurring cautionary theme in forums is unplanned pregnancy once cycles resume ('Ozempic babies'). None of this is proof of a fertility effect.
Context, not a protocol: subcutaneous once-weekly semaglutide is typically titrated from 0.25 mg upward (obesity labeling goes to 2.4 mg); PCOS off-label use often mirrors this with slow titration, and community practice sometimes stays at lower weekly doses. Actual dosing should follow product labeling and prescriber judgment.
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. Because return of ovulation can restore fertility, contraception counseling is essential and the drug should be stopped before conception (discontinue ~2 months prior per labeling) given lack of pregnancy safety data. Watch for pancreatitis, gallbladder disease, and additive GI effects/B12 issues when stacked with metformin, which is a common combination in this population.
A legitimate, increasingly used metabolic-first tool in insulin-resistant/obese PCOS: strong for weight, plausible for androgen lowering, unproven for ovulation as a primary endpoint. Reasonable to use for the metabolic driver with explicit contraception counseling, while being candid that the reproductive benefit is expected rather than demonstrated.
▶Kisspeptin-10EmergingAn upstream neuroendocrine drive-the-axis approach that is a research tool in PCOS, not a clinical therapy. Take it seriously as physiology, but not as something ready to prescribe.expand
An upstream neuroendocrine drive-the-axis approach that is a research tool in PCOS, not a clinical therapy. Take it seriously as physiology, but not as something ready to prescribe.
▸Full clinical story
Kisspeptin acts on GnRH neurons to stimulate pulsatile LH/FSH release, the drive needed for follicular maturation and ovulation. In PCOS the rationale is to directly restore an ovulatory gonadotropin signal rather than to correct the metabolic/androgen driver, positioning it opposite the metabolic-first lever central to this condition.
Honest grade: emerging, and barely so. The key human data are a proof-of-principle pilot embedded in an otherwise preclinical (rat model) paper: of 12 anovulatory women with PCOS given kisspeptin-54, only 2 ovulated, 1 grew a follicle without ovulating, 1 desensitized, and the rest had no follicular response. This is a first-in-human signal, not efficacy; effect was incomplete and heterogeneous. Grade confirmed as emerging but flagged as pilot-stage, and lean-PCOS phenotypes may respond differently.
Essentially none as a PCOS ovulation-induction practice. Kisspeptin-10 circulates in peptide/biohacking channels mainly for purported libido/HPG-axis effects in men, not for PCOS; there is no meaningful patient community using it to induce ovulation. Any such use would be anecdotal and unsupported.
No established PCOS dosing. Research protocols used kisspeptin-54 by injection (e.g. repeated ~6.4-12.8 nmol/kg s.c. dosing in the pilot), which differs from the kisspeptin-10 fragment sold in gray markets; these are not interchangeable and no protocol should be inferred.
Receptor desensitization with repeated/continuous exposure is a real, observed failure mode that can blunt rather than boost the axis. Research-grade peptide only; gray-market kisspeptin-10 lacks purity/sterility assurance, and using it for fertility bypasses the metabolic correction that is the actual first-line lever in this condition.
Mechanistically elegant and worth watching, but clinically premature: a 2/12 ovulation rate in a pilot is a signal, not a treatment. Not clinically ready; keep it in the research column and lead with metabolic correction.
▶TirzepatideDual GIP and GLP-1 receptor agonismexpand
▸Evidence, community & peer detail
No evidence rows yet.
- Positive20 corroboratinganecdotal
Cycle regularized quickly, weight loss, less brain fog/inflammation, fertility restored
Side effects: GI effects, conception risk
survivorshipr/PCOS
No peer data yet. Aggregates appear once ≥3 clinicians log an outcome.
▶MetforminStrongThe long-standing first-line metabolic agent in PCOS and the archetype of the metabolic-first lever: an insulin sensitizer that improves insulin resistance, modestly lowers androgens, and helps regularize cycles. Take it seriously; it is guideline-endorsed.expand
The long-standing first-line metabolic agent in PCOS and the archetype of the metabolic-first lever: an insulin sensitizer that improves insulin resistance, modestly lowers androgens, and helps regularize cycles. Take it seriously; it is guideline-endorsed.
▸Full clinical story
Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity (partly via AMPK activation), lowering circulating insulin. Since hyperinsulinemia amplifies ovarian/adrenal androgen production and suppresses SHBG, reducing insulin lowers free testosterone and eases the hyperandrogenic brake on ovulation, matching the condition's metabolic-correction-leads logic exactly.
Honest grade: strong. Metformin is embedded in the 2023 International Evidence-based PCOS Guideline and serves as the reference comparator ('gold-standard insulin sensitizer') in the PCOS inositol meta-analyses that inform that guideline, with hundreds of metformin-arm patients pooled; across these it improves insulin/metabolic parameters, waist-hip ratio and hirsutism and supports menstrual regularity (inositol showed non-inferiority for cycles). Effects on androgens and cycles are real but modest, and it is not primarily a weight-loss or fertility drug. Note the two citations here are inositol comparison meta-analyses in which metformin is the active comparator rather than metformin-primary trials, but they directly report metformin-arm outcomes and characterize it as the gold-standard agent. Grade confirmed strong on the basis of guideline endorsement and its established comparator role.
Anecdotal community signal: extremely widely used and discussed; patients report more regular cycles and some weight/appetite benefit, but GI upset (diarrhea, nausea) is the dominant complaint and a common reason for stopping. Many report better tolerance with extended-release formulations and slow titration with food, and it is frequently paired with inositol or, increasingly, GLP-1 RAs. This reflects experience, not controlled proof.
Context, not a protocol: commonly titrated to roughly 1500-2000 mg/day (often extended-release), started low and increased gradually to limit GI effects. Actual dosing follows prescriber judgment and renal function.
Dose-adjust or avoid in significant renal impairment; hold around iodinated contrast and acute illness given lactic acidosis risk. Long-term use can lower vitamin B12 (monitor), and GI effects stack additively with GLP-1 RAs when co-prescribed. If ovulation resumes, fertility can return; not a substitute for anti-androgen or contraceptive management where those are the goal.
The reference metabolic agent for insulin-resistant PCOS: safe, cheap, guideline-backed, with genuine but modest effects on androgens and cycles. A sensible first-line backbone that newer agents (GLP-1 RAs, inositol) are measured against and often combined with.
- Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. ↗
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ↗
Matching protocol templates
Browse all →Staggered hunger control, cost reduction, side effect modulation
Natural testosterone restoration, fertility support, HPTA recovery
Libido enhancement and erectile support
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.